Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 1.23 is 34% below its 5-year average of 1.86, near the low end of its 5-year range (1.04–2.37).
34.22% below its 12-month average of 1.87.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.29.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 26 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:02:05.157Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
1.23
EARNINGS PER SHARE (EPS) AVG TTM
1.87
EARNINGS PER SHARE (EPS) AVG 3Y
2.02
EARNINGS PER SHARE (EPS) AVG 5Y
1.86
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-34.22%
CURRENT VS 3Y AVG
-39.03%
CURRENT VS 5Y AVG
-33.75%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$808.29M
Earnings Per Share (EPS)
-0.20
TTM Avg
0.10
3Y Avg
-0.30
5Y Avg
-1.16
Market Cap
$818.90M
Earnings Per Share (EPS)
-0.23
TTM Avg
-0.22
3Y Avg
-0.29
5Y Avg
-0.62
Market Cap
$791.18M
Earnings Per Share (EPS)
-1.68
TTM Avg
0.05
3Y Avg
-1.18
5Y Avg
-0.72
Market Cap
$831.35M
Earnings Per Share (EPS)
-2.75
TTM Avg
-44.66
3Y Avg
-65.84
5Y Avg
-51.72
Market Cap
$788.35M
Earnings Per Share (EPS)
0.84
TTM Avg
0.43
3Y Avg
-11.54
5Y Avg
-7.53
Market Cap
$834.17M
Earnings Per Share (EPS)
-3.80
TTM Avg
-6.69
3Y Avg
-9.43
5Y Avg
-9.43
Market Cap
$777.55M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.23
3Y Avg
-1.23
5Y Avg
-1.23
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InMode Ltd. (INMD) | $811.05M | 1.23 | 1.87 | 2.02 | 1.86 |
| Gyre Therapeutics, Inc. (GYRE)vs › | $808.29M | -0.20 | 0.10 | -0.30 | -1.16 |
| Ardelyx, Inc. (ARDX)vs › | $818.90M | -0.23 | -0.22 | -0.29 | -0.62 |
| AdaptHealth Corp. (AHCO)vs › | $791.18M | -1.68 | 0.05 | -1.18 | -0.72 |
| Jade Biosciences, Inc. (JBIO)vs › | $831.35M | -2.75 | -44.66 | -65.84 | -51.72 |
| Mesa Laboratories, Inc. (MLAB)vs › | $788.35M | 0.84 | 0.43 | -11.54 | -7.53 |
| Alumis Inc. (ALMS)vs › | $834.17M | -3.80 | -6.69 | -9.43 | -9.43 |
| Attovia Therapeutics, Inc. (ATTO)vs › | $777.55M | N/A | -1.23 | -1.23 | -1.23 |
| Apnimed, Inc. (APMD)vs › | $844.65M | N/A | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $773.03M | -0.10 | -0.20 | -0.27 | -0.29 |
Trailing EPS (TTM)
$1.23
Forward EPS (Est.)
$1.30
P/E Ratio
11.5
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 1.45 |
| 2024-12-31 | 2.29 |
| 2023-12-31 | 2.37 |
| 2022-12-31 | 1.96 |
| 2021-12-31 | 2.03 |
| 2020-12-31 | 1.04 |
| 2019-12-31 | 1.05 |
| 2018-12-31 | 0.35 |
| 2017-12-31 | 0.14 |
| 2016-12-31 | 0.01 |
(FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown Quote observation: 2026-10-06T14:02:05.157Z. Historical observations retain their original dates. Historical series through 2026-10-05.
